Delcath Systems to Attend HC Wainwright’s 26th Annual Global Investment Conference

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that management will participate in an informal meeting during the HC Wainwright 26th Annual Global Investment Conference on Wednesday, September 11, 2024 at 11:00 a.m. Eastern Time at the Lotte New York Palace Hotel in New York City.

About Delcath Systems, Inc., HEPZATO KIT and CHEMOSAT
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company’s proprietary products, HEPZATO KIT (HEPZATO (melphalan) for injection/liver delivery system) and CHEMOSAT Liver Delivery System for Melphalan percutaneous liver perfusion (PHP), are designed to deliver high-dose chemotherapy to the liver while controlling systemic exposure and associated adverse events during a PHP procedure.